Organization
Division of Cancer Sciences
4 abstracts
Abstract
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).Org: Gustave Roussy Cancer Campus, EORTC Headquarters, Université Clermont Auvergne, Dermato-Oncology and CIC AP-HP Hôpital Saint Louis, Université de Versailles-Saint Quentin en Yvelines,
Abstract
Seasonal patterns in immunotherapy outcomes.Org: The University of Manchester and The Christie NHS Foundation Trust, The Christie NHS Foundation Trust, University of Manchester and The Christie NHS Foundation Trust, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Division of Cancer Sciences,
Abstract
Correlation between multiorgan immune-related adverse events and clinical outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC) treated with chemo-immunotherapy.Org: Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, The Christie NHS Foundation Trust, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).Org: Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, University Medical Center Utrecht, Sotiria General Hospital, Azienda Ospedaliero Universitaria Careggi, University of Florence, Centre Hospitalier Universitaire de Liège,